Brief: Firebrick Pharma Requests Trading Halt
11/09/2023 24:39
Sept 11 (Reuters) - Firebrick Pharma Ltd FRE.AX :
* REQUESTS TRADING HALT PENDING AN ANNOUNCEMENT ABOUT
RESULTS OF
ITS PHASE 3 COMMON COLD TRIAL
Source text for Eikon: ID:nASX8X4YhH
Further company coverage: FRE.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Firebrick Pharma
See all newsAustralia's Firebrick Pharma jumps on plan to launch Nasodine products in US retail market
Brief: Firebrick Pharma Receives A$293,000 Research And Development Tax Incentive
Brief: Firebrick Pharma Says Nasodine Composition Patent Granted In New Zealand
Brief: Firebrick Pharma Says Nasodine Patent Accepted In Canada
Brief: Firebrick Pharma Secures A$1.5 Million Via Placement